Pardon our appearance!

We are still working on the integration of this blog into our web site, so the content is a bit ahead of our graphic appearance.

Hedge Funds…Not Looking so Pharma Smart

Just a couple of days ago, Reuters reported that Pfizer “…is winning attention from some of the savviest hedge funds thanks to high-tech drugs and vaccines that it got when it paid $68 billion for Wyeth.” OK, I get it that it’s all about THE PIPELINE and buying Wyeth put quite a few new [...]